Imatinib is highly effective in treating cancers like chronic myeloid Leukemia (CML) and gastrointestinal stromal tumors (GIST) due to its targeted approach. It specifically inhibits the activity of BCR-ABL, a protein created by a genetic mutation in CML, and c-KIT, which drives GIST growth. By blocking these pathways, Imatinib prevents the rapid and uncontrolled growth of cancer cells, offering a highly effective treatment with fewer side effects compared to traditional chemotherapy.
One of the key factors in its success is that it targets cancer cells specifically, leaving normal cells largely unaffected. This precision makes it a cornerstone of modern cancer therapy, improving survival rates and quality of life for patients.
Imatinib’s global accessibility is also supported by Imatinib Exporters, who ensure that this life-saving medication reaches patients in various regions. These exporters play a crucial role in making Imatinib affordable and available worldwide, particularly in low-income countries where treatment options may be limited.
.
